You are here

A new Ebola vaccine promises complete protection in trials

Editage Insights | 2015年8月3日 | 3,071 浏览次数
A new Ebola vaccine promises complete protection in trials

rVSV-ZEBOV, an experimental Ebola vaccine, has successfully provided complete protection against Ebola infection in people who are at high risk of contracting the virus. The Public Health Agency of Canada developed this vaccine using an attenuated livestock virus engineered to produce an Ebola protein. In the trials conducted on 2,014 humans in Guinea, some subjects and their subsequent contacts were vaccinated immediately after they were exposed to an infected person, whereas some subsequent contacts were vaccinated three weeks later. The people who received immediate vaccination did not develop the disease. Though the results are promising, the size of the study was small and it remains to be seen whether the vaccine is as effective when given to a larger population. Moreover, it is not known for how long the protection lasts; further observation is required to understand this. The WHO has decided that the rVSV-ZEBOV vaccine will continue to be used in the current outbreak in Guinea as part of the clinical trial.

Read more in Nature.     


《意得辑专家视点》深信知识需要开放给所有大众并传播,因此我们鼓励读者重复发表我们的内容,重复发表形式可为在线或印刷。我们采用知识共享(Creative Commons license),只要您遵守以下事项,即可免费重复发表我们的内容:
  • 作者信息:请尊重我们的作者,他们花费了时间精力为您撰写这些有价值的内容,重复发表时加注作者信息。
  • 意得辑专家视点:必须注明文章出自《意得辑专家视点》。
  • 表达您的情意:您可以加句“前往《意得辑专家视点》阅读全文”之类的话,啊,还有,别忘了加上文章链接。
  • 重复使用图片:要使用某些文章的图片必须事先取得许可,并加注图片原始出处。
  • 镶嵌代码:要重复使用这篇文章最简单的方式就是将下面的代码复制贴上您的页面!